About Cubist Pharmaceuticals (NASDAQ:CBST)
Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Cubist Pharmaceuticals (NASDAQ:CBST) Frequently Asked Questions
What is Cubist Pharmaceuticals' stock symbol?
Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."
How were Cubist Pharmaceuticals' earnings last quarter?
Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its quarterly earnings results on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.54. The biopharmaceutical company had revenue of $309.20 million for the quarter, compared to analysts' expectations of $305.50 million. Cubist Pharmaceuticals's revenue for the quarter was up 16.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.41 EPS. View Cubist Pharmaceuticals' Earnings History.
Who are some of Cubist Pharmaceuticals' key competitors?
Some companies that are related to Cubist Pharmaceuticals include CSL (CSL), Grifols SA, Barcelona (GRFS), Jazz Pharmaceuticals (JAZZ), ProMetic Life Sciences (PLI), Sirtex Medical (SRX), Mirati Therapeutics (MRTX), Theratechnologies (TH), Organigram (OGI), SIGA Technologies (SIGA), XOMA (XOMA), VBI Vaccines (VBIV), Osiris Therapeutics (OSIR), Sevion Therapeutics (SVON), Anavex Life Sciences (AVXL), Trillium Therapeutics (TRIL), ContraFect (CFRX), Medgenics (GNMX) and Concordia International (CXR).
How do I buy Cubist Pharmaceuticals stock?
Shares of Cubist Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Cubist Pharmaceuticals?
Cubist Pharmaceuticals' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.
MarketBeat Community Rating for Cubist Pharmaceuticals (CBST)MarketBeat's community ratings are surveys of what our community members think about Cubist Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cubist Pharmaceuticals (NASDAQ:CBST) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Cubist Pharmaceuticals (NASDAQ:CBST) Earnings History and Estimates Chart
Cubist Pharmaceuticals (NASDAQ CBST) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/21/2014||Q314||$0.04||$0.58||$305.50 million||$309.20 million||View||Listen|
|7/22/2014||Q214||$0.37||$0.23||$299.60 million||$294.40 million||View||N/A|
|4/22/2014||Q114||$0.34||$0.10||$285.24 million||$261.20 million||View||N/A|
|1/23/2014||Q413||$0.33||$0.29||$285.47 million||$299.70 million||View||N/A|
|7/18/2013||Q2 2013||$0.55||$0.42||$254.93 million||$258.80 million||View||N/A|
|4/18/2013||Q1 2013||$0.50||$0.34||$243.55 million||$229.90 million||View||N/A|
|1/23/2013||Q4 2012||$0.48||$0.51||$246.42 million||$245.90 million||View||N/A|
Cubist Pharmaceuticals (NASDAQ:CBST) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cubist Pharmaceuticals (NASDAQ:CBST)
No dividend announcements for this company have been tracked by MarketBeat.com
Cubist Pharmaceuticals (NASDAQ CBST) Insider Trading and Institutional Ownership History
Cubist Pharmaceuticals (NASDAQ CBST) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/1/2014||Steven C Gilman||EVP||Sell||48,125||$65.39||$3,146,893.75|| |
|8/19/2014||Gregory Stea||SVP||Sell||38,326||$65.88||$2,524,916.88|| |
|8/18/2014||Nancy J Hutson||Director||Sell||9,000||$65.00||$585,000.00|| |
|8/18/2014||Robert J Perez||COO||Sell||1,003||$63.68||$63,871.04|| |
|7/28/2014||Steven C Gilman||EVP||Sell||40,625||$61.57||$2,501,281.25|| |
|5/15/2014||Michael Bonney||CEO||Sell||3,036||$67.50||$204,930.00||175,859|| |
|5/15/2014||Robert Perez||COO||Sell||1,518||$67.50||$102,465.00||45,869|| |
|5/15/2014||Steven Gilman||EVP||Sell||16,340||$67.82||$1,108,178.80||27,598|| |
|5/14/2014||Michael Bonney||CEO||Sell||3,840||$69.00||$264,960.00||172,645|| |
|5/14/2014||Robert Perez||COO||Sell||2,400||$69.00||$165,600.00||44,262|| |
|5/14/2014||Steven Gilman||EVP||Sell||1,680||$69.00||$115,920.00||26,313|| |
|3/6/2014||Gregory Stea||SVP||Sell||19,889||$79.74||$1,585,948.86||16,276|| |
|2/27/2014||Mark Corrigan||Director||Sell||5,000||$80.00||$400,000.00||5,498|| |
|2/27/2014||Michael Bonney||CEO||Sell||100,000||$81.25||$8,125,000.00||168,485|| |
|2/27/2014||Robert Perez||COO||Sell||30,000||$80.18||$2,405,400.00||41,662|| |
|2/20/2014||Michael Bonney||CEO||Sell||3,112||$75.60||$235,267.20||168,485|| |
|2/3/2014||Kenneth Bate||Director||Sell||6,250||$72.15||$450,937.50||7,914|| |
|1/15/2014||Gregory Stea||SVP||Sell||5,312||$74.90||$397,868.80||14,189|| |
|1/15/2014||Robert Perez||COO||Sell||10,000||$74.95||$749,500.00||37,612|| |
|1/13/2014||Robert Perez||COO||Sell||10,000||$72.95||$729,500.00||37,612|| |
|1/9/2014||Kenneth Bate||Director||Sell||10,000||$70.00||$700,000.00||7,914|| |
|1/2/2014||Steven Gilman||EVP||Sell||25,000||$67.82||$1,695,500.00||23,540|| |
|12/2/2013||Kenneth Bate||Director||Sell||12,500||$67.63||$845,375.00||7,914|| |
|9/9/2013||Martin Rosenberg||Director||Sell||15,472||$65.00||$1,005,680.00|| |
|8/16/2013||Robert Perez||COO||Sell||1,024||$60.55||$62,003.20||37,536|| |
|7/31/2013||Gregory Stea||SVP||Sell||33,750||$61.29||$2,068,537.50|| |
|7/26/2013||Nancy J Hutson||Director||Sell||5,000||$53.87||$269,350.00|| |
|7/19/2013||Gregory Stea||SVP||Sell||4,375||$55.00||$240,625.00|| |
|6/3/2013||Kenneth Bate||Director||Sell||2,500||$54.95||$137,375.00|| |
|6/3/2013||Steven C Gilman||EVP||Sell||15,125||$54.49||$824,161.25|| |
|5/24/2013||Mark Corrigan||Director||Sell||14,000||$54.60||$764,400.00|| |
|5/22/2013||J Matthew Singleton||Director||Sell||27,500||$55.48||$1,525,700.00|| |
|5/20/2013||Charles Anthony Laranjeira||SVP||Sell||14,000||$51.43||$720,020.00|| |
|5/20/2013||Michael W Bonney||CEO||Sell||60,000||$50.00||$3,000,000.00|| |
|5/20/2013||Robert J Perez||COO||Sell||15,000||$49.98||$749,700.00|| |
|5/16/2013||Michael W Bonney||CEO||Sell||2,400||$47.88||$114,912.00|| |
|5/16/2013||Robert J Perez||COO||Sell||1,500||$47.88||$71,820.00|| |
|5/16/2013||Steven C Gilman||EVP||Sell||1,201||$48.88||$58,704.88|| |
|5/15/2013||Kenneth Bate||Director||Sell||2,500||$48.41||$121,025.00|| |
|5/15/2013||Michael W Bonney||CEO||Sell||2,979||$48.41||$144,213.39|| |
|5/15/2013||Robert J Perez||COO||Sell||1,490||$48.41||$72,130.90|| |
|5/15/2013||Steven C Gilman||EVP||Sell||1,017||$48.41||$49,232.97|| |
|5/14/2013||Michael W Bonney||CEO||Sell||3,753||$49.18||$184,572.54|| |
|5/14/2013||Robert J Perez||COO||Sell||2,346||$49.18||$115,376.28|| |
|5/14/2013||Steven C Gilman||EVP||Sell||1,135||$49.18||$55,819.30|| |
Cubist Pharmaceuticals (NASDAQ CBST) News Headlines
Cubist Pharmaceuticals (NASDAQ:CBST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cubist Pharmaceuticals (NASDAQ:CBST) Income Statement, Balance Sheet and Cash Flow Statement
Cubist Pharmaceuticals (NASDAQ CBST) Stock Chart for Saturday, January, 20, 2018